Clinical-stage biopharmaceutical company focused on developing off-the-shelf gamma delta T cell therapies for cancer.
Adicet Bio, Inc., headquartered in Boston, Massachusetts, is at the forefront of biotechnology innovation, specializing in the discovery and development of allogeneic gamma delta T cell therapies designed to combat cancer and other diseases. The company focuses on leveraging gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. These advancements are aimed at enhancing precise tumor targeting, fostering both innate and adaptive anti-tumor immune responses, and promoting prolonged therapeutic efficacy in patients.
At the forefront of Adicet Bio's pipeline is ADI-001, currently undergoing Phase I clinical trials for the treatment of non-Hodgkin's lymphoma. This product exemplifies the company's commitment to advancing novel therapies that address significant unmet medical needs in oncology. Additionally, Adicet Bio is actively developing ADI-002, which is in preclinical stages and holds promise for treating various solid tumors.
In addition to its innovative therapeutic approaches, Adicet Bio pursues strategic collaborations and partnerships to further bolster its research and development efforts. By fostering alliances within the biopharmaceutical community, the company aims to accelerate the translation of its cutting-edge technologies into transformative treatments for patients worldwide.
Founded on a mission to pioneer next-generation immunotherapies, Adicet Bio continues to push the boundaries of scientific discovery. With a steadfast commitment to scientific rigor and patient-centric innovation, the company remains dedicated to revolutionizing cancer treatment paradigms and improving outcomes for individuals facing complex and challenging diseases.